Galahad Patient Summary
This trial is looking for men in the US with metastatic prostate cancer and certain genetic alterations within their tumors. Patients who progress on prior chemotherapy (taxane) and androgen receptor targeted therapy are eligible for this study.
The Galahad clinical trial will assess the effectiveness and safety of an investigational medication in men with metastatic prostate cancer with certain genetic alterations (also called mutations or biomarkers) to their tumor.
This is an open‐label study meaning the patient and researcher will know the investigational medication being studied. All patients will receive the investigational medication. This trial is looking for patients whose tumor progressed after prior treatment with chemotherapy (for example, Taxotere® ) and androgen receptor treatments for prostate cancer (for example, Xtandi® , Zytiga®).
Galahad is a phase 2 clinical trial that will enroll approximately 215 participants. The trial began in 2016 and the primary completion date is in 2019.
Possible patient benefits: Eligible participants may receive all study‐required care at no charge. This includes investigational medication, study evaluations and procedures.
Possible patient risks: There are known and possibly unknown side effects from the investigational medication.
To learn more about the Galahad clinical trial and to find out if you may be eligible, please visit www.clinicaltrials.gov (Study Identifier: NCT02854436) or ClinicalTrials.gov link with study locations
Organization: Janssen Research & Development, LLC
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.